You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 123 No. 12, December 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Safety of In Vivo Adenovirus-Mediated Thymidine Kinase Treatment of Oral Cancer

Duane A. Sewell, MD; Daqing Li, MD; Ling Duan, MS; William H. Westra, MD; Bert W. O'Malley, Jr, MD

Arch Otolaryngol Head Neck Surg. 1997;123(12):1298-1302.


Abstract

Background
Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene (tk) is one of the most effective gene therapy strategies for solid tumors in experimental animal studies. Foundational animal studies in an oral cancer model have demonstrated significant antitumor effects and improved animal survival using this treatment strategy.

Objective
To assess the safety of adenovirusmediated transfer of the herpes simplex virus tk gene for the treatment of oral cancer.

Design
Oral tumors were established in C3H/HeJ mice and were treated with tk followed by systemic ganciclovir administration. Polymerase chain reaction amplification techniques were used to screen local surrounding tissues and distant organs for the presence of the adenoviral construct. Microscopic examination of the tissues was performed to determine the cytopathic effects of the vector. Blood samples were obtained from the animals to test for liver, renal, and bone marrow function after treatment.

Results
The adenoviral vector was present in the livers, lungs, and kidneys of animals treated with the maximal single injection dose of 2x109 plaque forming units (pfu). No vector was noted systemically after delivery of an equally effective low dose of 1x108 pfu. Microscopic examination revealed no cytopathic effects in distant organs despite the presence of vector. Results of liver and renal function tests revealed no differences between treated and control animals. There was no statistical difference in white blood cell count, hematocrit, or platelet count between animals treated with ganciclovir and control animals.

Conclusions
Based on these results, the direct delivery of adenovirus-tk followed by ganciclovir administration appears both efficacious and safe in an animal model. However, serum evaluation for adenovirus vector and screening organ function studies should be included in human protocols using this gene therapy scheme.

Arch Otolaryngol Head Neck Surg. 1997;123:1298-1302



Author Affiliations

From the Departments of Otolaryngology—Head and Neck Surgery (Drs Sewell, Li, and O'Malley and Ms Duan) and Pathology (Dr Westra), Johns Hopkins Medical Institutions, Baltimore, Md.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Retargeting to EGFR Enhances Adenovirus Infection Efficiency of Squamous Cell Carcinoma
Blackwell et al.
Arch Otolaryngol Head Neck Surg 1999;125:856-863.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.